Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr

Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023

Takeda pledges support to HAE patients through its ‘Sunrise patient support program’

Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support

AIIA and CCRAS jointly organised session for research and education in Ayush

Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc

Venus Remedies bolsters its position in oncology space with marketing approval from Philippines, Iraq

The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region

Dr Bharati Pravin Pawar launches Phase-III of Thalassemia Bal Sewa Yojana

Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease

Zydus receives final approval from the USFDA for Sucralfate Tablets USP, 1 gram

Brain Cells are starved of energy when autophagy malfunctions: New Study

The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments

Hyderabad startup’s Physiotherapy monitoring device ‘Pheezee’ receives USFDA

Pheezee is designed to assess musculoskeletal and neuromuscular health.

Mandaviya reviews organ donation policy

Organ Transplants triple across the country; rise from 5000 (2013) to more than 15000 in 2022

Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr

The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year